Article

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

2021-12-14

Abstract excerpt

<h4>Background</h4> A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant in highly vaccinated populations has raised concerns about the effectiveness of current vaccines. <h4>Methods</h4> We used a test-negative case-control design to estimate vaccine effectiveness (VE) against symptomatic disease caused by the Omicron and Delta variants in England. VE was calculated after primary immunisati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62ee0ba9-60c9-529d-8cf6-b78be2ba54c9
DOI: 10.1101/2021.12.14.21267615

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernDOI 10.1101/2021.12.14.21267615Read

COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in EnglandSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Effectiveness of XBB.1.5 Vaccines Against Omicron SubvariantsSemantic proximity Read

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read

COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Semantic proximity Read

Effectiveness of BNT162b2 COVID-19 Vaccination in Prevention of Hospitalisations and Severe Disease in Adults with Delta (B.1.617.2) and Omicron (B.1.1.529) Variant SARS-CoV-2 Infection: A Prospective Test Negative Case-Control StudySemantic proximity Read

Effectiveness of COVID-19 vaccines against delta variant (B.1.617.2): A meta-analysisSemantic proximity Read

Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variantSemantic proximity Read

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 YearsSemantic proximity Read

Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, EnglandSemantic proximity Read

Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United StatesSemantic proximity Read

Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPPSemantic proximity Read